HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
REGULATORY AFFAIRS ASSOCIATE November 9, 2018News JOB DESCRIPTION Responsible for compliance with applicable procedures. This
SALT LAKE CITY, USA, May 8, 2017 – LSK BioPharma (LSKB, Company) announced today that it has received approval from the Korean Ministry of Food and Drug Safety (MFDS) to initiate a phase 2 clinical trial of apatinib, the Company’s proprietary angiogenesis inhibitor, in colorectal cancer. The Company is already conducting a global phase 3 clinical trial of apatinib in advanced gastric cancer, an indication for which the drug has already received market approval in China.
“We saw promising indications of efficacy in metastatic colorectal cancer patients in our phase 1/2a clinical study of apatinib,” noted Dr. Sung Chul Kim, President of LSK BioPharma, “We look forward to seeing the results of this phase 2 trial considering the exceptional tolerability profile that has been demonstrated and the clinical benefits for such a compound in metastatic colorectal cancer.”